CYCN

SEC source: 0001193125-26-388146 · ownership.xml · derivative · entry 1

Pernice Michelle Patricia · CIK 0002126413 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,445

Underlying: Common Stock · 48,445 shares

Expires 2036-09-09

F1 · derivative.exercise_date: This option represents the right to purchase 48,445 shares of the Issuer's common stock and will vest in equal monthly installments through September 9, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

SEC source: 0001193125-26-388142 · ownership.xml · derivative · entry 1

Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner

Fairmount Healthcare Co-Invest VI L.P. · CIK 0002124208 · Director · 10% owner

Kiselak Tomas · CIK 0001830177 · Director · 10% owner

Harwin Peter Evan · CIK 0001663607 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By: Tomas Kiselak

Disclosed balance after: 48,445

Underlying: Common Stock · 48,445 shares

Expires 2036-09-09

F1 · derivative.exercise_date: This option represents a right to purchase 48,445 shares of the Issuer's common stock. This option will vest in equal monthly installments through September 9, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

F2 · ownership.direct: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. ("Fund II") and Fairmount Healthcare Co-Invest VI L.P. ("Co-Invest"). Peter Harwin and Tomas Kiselak are the managers of Fairmount. Under Mr. Kiselak's arrangement with Fairmount, Mr. Kiselak holds the option for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Kiselak is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001193125-26-388144 · ownership.xml · derivative · entry 1

Shah Nimish P · CIK 0001698082 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,445

Underlying: Common Stock · 48,445 shares

Expires 2036-09-09

F1 · derivative.exercise_date: This option represents the right to purchase 48,445 shares of the Issuer's common stock and will vest in equal monthly installments through September 9, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

F2 · ownership.direct: Under an agreement between the Reporting Person and Venrock Management, LLC (the "Management Company"), the Reporting Person is deemed to hold the reported option and the shares underlying the option for the sole benefit of the Management Company and must exercise the reported option solely upon the direction of the Management Company, which is entitled to the shares underlying the option. The Management Company may be deemed the indirect beneficial owner of the shares underlying the option, and the Reporting Person may be deemed the indirect beneficial owner of the reported shares underlying the option through his interest in the Management Company. The Reporting Person disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein.

SEC source: 0001193125-26-388136 · ownership.xml · derivative · entry 1

Gottesdiener Andrew · CIK 0001972292 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,445

Underlying: Common Stock · 48,445 shares

Expires 2036-09-09

F1 · derivative.exercise_date: This option represents the right to purchase 48,445 shares of the Issuer's common stock and will vest in equal monthly installments through September 9, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

F2 · ownership.direct: Under an agreement between the Reporting Person and Venrock Management, LLC (the "Management Company"), the Reporting Person is deemed to hold the reported option and the shares underlying the option for the sole benefit of the Management Company and must exercise the reported option solely upon the direction of the Management Company, which is entitled to the shares underlying the option. The Management Company may be deemed the indirect beneficial owner of the shares underlying the option, and the Reporting Person may be deemed the indirect beneficial owner of the reported shares underlying the option through his interest in the Management Company. The Reporting Person disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein.

SEC source: 0001193125-26-355707 · ownership.xml · derivative · entry 3

Graul Regina Margaret · CIK 0002002981 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 55,849 shares

Expires 2034-08-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The Reporting Person was granted an option on August 5, 2024 to purchase up to 55,849 shares of the Corporation's common stock pursuant to the 2019 Equity Incentive Plan, vesting ratably in monthly installments over a 48-month period commencing August 31, 2024 and ending July 31, 2028, provided that the Reporting Person remained employed by Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions. On July 17, 2026, the Issuer's Board of Directors elected to accelerate in full the vesting of all then unvested options and all then unvested restricted shares for the Reporting Person.

F1 · derivative.exercise_date: The Reporting Person was granted an option on August 5, 2024 to purchase up to 55,849 shares of the Corporation's common stock pursuant to the 2019 Equity Incentive Plan, vesting ratably in monthly installments over a 48-month period commencing August 31, 2024 and ending July 31, 2028, provided that the Reporting Person remained employed by Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions. On July 17, 2026, the Issuer's Board of Directors elected to accelerate in full the vesting of all then unvested options and all then unvested restricted shares for the Reporting Person.

SEC source: 0001193125-26-355707 · ownership.xml · nonDerivative · entry 2

Graul Regina Margaret · CIK 0002002981 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 107,523

F2 · kind: The Reporting Person exercised the option in full on August 14, 2026 and paid for the exercise by means of a cashless exercise, forfeiting options to purchase 48,629 shares as payment to the Issuer for the full exercise price.

SEC source: 0001193125-26-355707 · ownership.xml · nonDerivative · entry 1

Graul Regina Margaret · CIK 0002002981 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 156,152

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The Reporting Person was granted an option on August 5, 2024 to purchase up to 55,849 shares of the Corporation's common stock pursuant to the 2019 Equity Incentive Plan, vesting ratably in monthly installments over a 48-month period commencing August 31, 2024 and ending July 31, 2028, provided that the Reporting Person remained employed by Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions. On July 17, 2026, the Issuer's Board of Directors elected to accelerate in full the vesting of all then unvested options and all then unvested restricted shares for the Reporting Person.

SEC source: 0001193125-26-355721 · ownership.xml · derivative · entry 2

CHICKO RHONDA M. · CIK 0001740376 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 25,000 shares

Expires 2035-08-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The Reporting Person was granted an option on August 7, 2025 to purchase up to 25,000 shares of the Corporation's common stock pursuant to the Issuer's 2019 Equity Incentive Plan. These 25,000 shares provided for vesting as follows: (i) 8,750 shares became immediately exercisable, and (ii) the remaining 16,250 shares were to vest ratably in monthly installments commencing August 31, 2025 and ending on February 28, 2028, provided that the Reporting Person remained as a consultant or employee of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions. On July 17, 2026, the Issuer's Board of Directors elected to accelerate in full the vesting of all then unvested options for the Reporting Person. The Reporting Person exercised the option in full on August 14, 2026 and paid for the exercise by means of a cash payment to the Issuer for the full purchase price.

F1 · derivative.exercise_date: The Reporting Person was granted an option on August 7, 2025 to purchase up to 25,000 shares of the Corporation's common stock pursuant to the Issuer's 2019 Equity Incentive Plan. These 25,000 shares provided for vesting as follows: (i) 8,750 shares became immediately exercisable, and (ii) the remaining 16,250 shares were to vest ratably in monthly installments commencing August 31, 2025 and ending on February 28, 2028, provided that the Reporting Person remained as a consultant or employee of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions. On July 17, 2026, the Issuer's Board of Directors elected to accelerate in full the vesting of all then unvested options for the Reporting Person. The Reporting Person exercised the option in full on August 14, 2026 and paid for the exercise by means of a cash payment to the Issuer for the full purchase price.

SEC source: 0001193125-26-355721 · ownership.xml · nonDerivative · entry 1

CHICKO RHONDA M. · CIK 0001740376 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,018

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The Reporting Person was granted an option on August 7, 2025 to purchase up to 25,000 shares of the Corporation's common stock pursuant to the Issuer's 2019 Equity Incentive Plan. These 25,000 shares provided for vesting as follows: (i) 8,750 shares became immediately exercisable, and (ii) the remaining 16,250 shares were to vest ratably in monthly installments commencing August 31, 2025 and ending on February 28, 2028, provided that the Reporting Person remained as a consultant or employee of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions. On July 17, 2026, the Issuer's Board of Directors elected to accelerate in full the vesting of all then unvested options for the Reporting Person. The Reporting Person exercised the option in full on August 14, 2026 and paid for the exercise by means of a cash payment to the Issuer for the full purchase price.

SEC source: 0001193125-26-309048 · ownership.xml · derivative · entry 5

Hecht Peter M · CIK 0001478485 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 351,037 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On May 19, 2023, the reporting person purchased directly from the Issuer 351,037 shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") at a price of $8.68 per share in a private placement transaction pursuant to the Stock Purchase Agreement dated as of March 31, 2023 between the reporting person and the Issuer. The Series A Preferred Stock is convertible to Common Stock on a one-for-one basis at the option of the holder thereof. On July 16, 2026, the reporting person converted all 351,037 shares of Series A Convertible Preferred Stock into 351,037 shares of Common Stock.

F1 · price: On May 19, 2023, the reporting person purchased directly from the Issuer 351,037 shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") at a price of $8.68 per share in a private placement transaction pursuant to the Stock Purchase Agreement dated as of March 31, 2023 between the reporting person and the Issuer. The Series A Preferred Stock is convertible to Common Stock on a one-for-one basis at the option of the holder thereof. On July 16, 2026, the reporting person converted all 351,037 shares of Series A Convertible Preferred Stock into 351,037 shares of Common Stock.

F1 · derivative.exercise_date: On May 19, 2023, the reporting person purchased directly from the Issuer 351,037 shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") at a price of $8.68 per share in a private placement transaction pursuant to the Stock Purchase Agreement dated as of March 31, 2023 between the reporting person and the Issuer. The Series A Preferred Stock is convertible to Common Stock on a one-for-one basis at the option of the holder thereof. On July 16, 2026, the reporting person converted all 351,037 shares of Series A Convertible Preferred Stock into 351,037 shares of Common Stock.

F1 · derivative.expiration_date: On May 19, 2023, the reporting person purchased directly from the Issuer 351,037 shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") at a price of $8.68 per share in a private placement transaction pursuant to the Stock Purchase Agreement dated as of March 31, 2023 between the reporting person and the Issuer. The Series A Preferred Stock is convertible to Common Stock on a one-for-one basis at the option of the holder thereof. On July 16, 2026, the reporting person converted all 351,037 shares of Series A Convertible Preferred Stock into 351,037 shares of Common Stock.

F1 · derivative.underlying_shares: On May 19, 2023, the reporting person purchased directly from the Issuer 351,037 shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") at a price of $8.68 per share in a private placement transaction pursuant to the Stock Purchase Agreement dated as of March 31, 2023 between the reporting person and the Issuer. The Series A Preferred Stock is convertible to Common Stock on a one-for-one basis at the option of the holder thereof. On July 16, 2026, the reporting person converted all 351,037 shares of Series A Convertible Preferred Stock into 351,037 shares of Common Stock.

F3 · balance_after: All options to purchase Common Stock previously held by the reporting person were cancelled on July 16, 2026. As a result, the reporting person no longer holds options to purchase Common Stock.

SEC source: 0001193125-26-309048 · ownership.xml · nonDerivative · entry 1

Hecht Peter M · CIK 0001478485 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 910,240

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On May 19, 2023, the reporting person purchased directly from the Issuer 351,037 shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") at a price of $8.68 per share in a private placement transaction pursuant to the Stock Purchase Agreement dated as of March 31, 2023 between the reporting person and the Issuer. The Series A Preferred Stock is convertible to Common Stock on a one-for-one basis at the option of the holder thereof. On July 16, 2026, the reporting person converted all 351,037 shares of Series A Convertible Preferred Stock into 351,037 shares of Common Stock.

F1 · price: On May 19, 2023, the reporting person purchased directly from the Issuer 351,037 shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") at a price of $8.68 per share in a private placement transaction pursuant to the Stock Purchase Agreement dated as of March 31, 2023 between the reporting person and the Issuer. The Series A Preferred Stock is convertible to Common Stock on a one-for-one basis at the option of the holder thereof. On July 16, 2026, the reporting person converted all 351,037 shares of Series A Convertible Preferred Stock into 351,037 shares of Common Stock.

SEC source: 0000950170-25-106532 · ownership.xml · derivative · entry 1

CHICKO RHONDA M. · CIK 0001740376 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2035-08-06

F1 · derivative.exercise_date: The Reporting Person was granted an option to purchase up to 25,000 shares of the Corporation's common stock pursuant to the 2019 Equity Incentive Plan. These 25,000 shares vest as follows: (i) 8,750 shares are immediately exercisable, and (ii) the remaining 16,250 shares vest ratably in monthly installments commencing August 31, 2025 and ending on February 28, 2028, provided that the Reporting Person remains as a consultant or employee of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions.

SEC source: 0000950170-25-046280 · ownership.xml · nonDerivative · entry 1

Hecht Peter M · CIK 0001478485 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 559,203

F1 · shares: On March 25, 2025, the reporting person purchased directly from the Issuer 181,818 shares of Common Stock for a total purchase price of approximately $500,000 (or $2.75 per share) in a private placement transaction pursuant to the Stock Purchase Agreement dated as of March 21, 2025 by and among the Issuer and the investors named therein.

SEC source: 0000950170-25-046099 · ownership.xml · nonDerivative · entry 1

Higgins Michael J · CIK 0001478521 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,740

F1 · shares: On March 25, 2025, the reporting person purchased directly from the Issuer 9,090 shares of Common Stock for a total purchase price of approximately $25,000 (or $2.75 per share) in a private placement transaction pursuant to the Stock Purchase Agreement dated as of March 21, 2025 by and among the Issuer and the investors named therein.

SEC source: 0000902664-24-006775 · ownership.xml · nonDerivative · entry 1

Slate Path Capital LP · CIK 0001559706 · 10% owner

Greenspan David Gerald · CIK 0001820641 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 0

F1 · shares: The number of shares reported herein reflect the one-for-twenty reverse stock split effected by the Issuer on May 15, 2023.

F2 · ownership.nature: The securities to which this filing relates were held by certain funds (the "Slate Path Funds"). Slate Path Capital LP (the "Investment Manager"), a Delaware limited partnership acts as the investment manager of the Slate Path Funds. Mr. David Greenspan serves as the managing member of Jades GP, LLC, a Delaware limited liability company and the general partner of the Investment Manager. The filing of this statement shall not be deemed an admission that either Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any.

SEC source: 0000950170-24-092733 · ownership.xml · derivative · entry 1

Graul Regina Margaret · CIK 0002002981 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,849

Underlying: Common Stock · 55,849 shares

Expires 2034-08-05

F1 · derivative.exercise_date: The Reporting Person was granted an option to purchase up to 55,849 shares of the Corporation's common stock pursuant to the 2019 Equity Incentive Plan. These 55,849 shares vest ratably in monthly installments over a 48-month period commencing August 31, 2024 and ending July 31, 2028, provided that the Reporting Person remains employed by Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions.

SEC source: 0000950170-24-007917 · ownership.xml · nonDerivative · entry 1

Graul Regina Margaret · CIK 0002002981 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,303

F1 · shares: The Reporting Person was granted 50,000 shares of restricted stock pursuant to the Cyclerion Therapeutics, Inc. 2019 Equity Incentive Plan. 10,000 of the shares vest immediately and the remaining 40,000 shares are subject to vesting ratably over a 48-month period, provided that the Reporting Person remains employed by Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions.

SEC source: 0000950170-24-007920 · ownership.xml · nonDerivative · entry 1

Hecht Peter M · CIK 0001478485 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 377,385

F1 · shares: The Reporting Person was granted 15,000 shares of restricted stock pursuant to the Cyclerion Therapeutics, Inc. 2019 Equity Incentive Plan. These 15,000 shares are subject to vesting over a 47- month period, provided that the Reporting Person remains a consultant to the Cyclerion Therapeutics or a member of the board of directors of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions.

SEC source: 0000950170-23-067738 · ownership.xml · nonDerivative · entry 2

Hecht Peter M · CIK 0001478485 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 362,385

F2 · shares: The Reporting Person was granted 15,000 shares of restricted stock pursuant to the Cyclerion Therapeutics, Inc. 2019 Equity Incentive Plan. These 15,000 shares are subject to vesting over a 48- month period, provided that the Reporting Person remains a consultant to the Cyclerion Therapeutics or a member of the board of directors of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions.

SEC source: 0000950170-23-067740 · ownership.xml · nonDerivative · entry 1

MCGUIRE TERRANCE · CIK 0001117003 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,552

F1 · shares: The Reporting Person was granted 5,000 shares of restricted stock pursuant to the Cyclerion Therapeutics, Inc. 2019 Equity Incentive Plan. 2,500 of these shares vest immediately and the remaining 2,500 of these shares vest over the next 6 months, provided that the Reporting Person remains as a director of Cylerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions.

SEC source: 0000950170-23-067738 · ownership.xml · nonDerivative · entry 1

Hecht Peter M · CIK 0001478485 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 347,385

F1 · shares: The Reporting Person was granted 20,000 shares of restricted stock pursuant to the Cyclerion Therapeutics, Inc. 2019 Equity Incentive Plan. 2,500 of the shares vest immediately and the remaining 17,500 shares are subject to vesting ratably over a 42-month period, provided that the Reporting Person remains as a director of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions.

SEC source: 0000950170-23-067736 · ownership.xml · nonDerivative · entry 2

DESOUZA ERROL B · CIK 0001213895 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

F2 · shares: The Reporting Person was granted 30,000 shares of restricted stock pursuant to the Cyclerion Therapeutics, Inc. 2019 Equity Incentive Plan. 3,750 of these shares vest immediately and the remaining 26,250 shares vest ratably over a 42-month period, provided that the Reporting Person remains as Chair of the Board of Directors of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions.

SEC source: 0000950170-23-067736 · ownership.xml · nonDerivative · entry 1

DESOUZA ERROL B · CIK 0001213895 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

F1 · shares: The Reporting Person was granted 20,000 shares of restricted stock pursuant to the Cyclerion Therapeutics, Inc. 2019 Equity Incentive Plan. 2,500 of these shares vest immediately and the remaining 17,500 shares vest ratably over a 42-month period, provided that the Reporting Person remains as a director of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions.

SEC source: 0000950170-23-067734 · ownership.xml · nonDerivative · entry 1

Hyman Steven · CIK 0001656506 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

F1 · shares: The Reporting Person was granted 20,000 shares of restricted stock pursuant to the Cyclerion Therapeutics, Inc. 2019 Equity Incentive Plan. 2,500 of the shares vest immediately and the remaining 17,500 shares are subject to vesting ratably over a 42-month period, provided that the Reporting Person remains as a director of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions.

SEC source: 0000899243-23-018047 · doc4.xml · nonDerivative · entry 1

MCGUIRE TERRANCE · CIK 0001117003 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Polaris Venture Management Co. II, L.L.C.

Disclosed balance after: 0

F1 · balance_after: On May 15, 2023, the Issuer effected a 1-for-20 reverse stock split of all of its shares of Common Stock resulting in a corresponding reduction of the Reporting Person's direct and indirect ownership of Common Stock.

F2 · ownership.nature: The Reporting Person and Jonathan Flint ("Flint") are the managing members of Polaris Venture Management Co. II, L.L.C., the beneficial owner of the securities. Each of the Reporting Person and Flint disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

SEC source: 0001140361-23-026101 · form4.xml · derivative · entry 5

Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 351,037

Underlying: Common Stock · 351,037 shares

Expires not disclosed

F1 · shares: On May 19, 2023, the reporting person purchased directly from the Issuer 225,000 shares of Common Stock and 351,037 shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") for a total purchase price of approximately $5,000,000 (or $8.68 per share) in a private placement transaction pursuant to the Stock Purchase Agreement dated as of March 31, 2023 between the reporting person and the Issuer. The Series A Preferred Stock may be converted to Common Stock on a one-for-one basis at the option of the holder thereof. The reporting person has agreed not to convert his Series A Preferred Stock to the extent such conversion would require shareholder approval pursuant to Nasdaq listing rules and such shareholder approval has not been obtained.

F1 · derivative.exercise_date: On May 19, 2023, the reporting person purchased directly from the Issuer 225,000 shares of Common Stock and 351,037 shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") for a total purchase price of approximately $5,000,000 (or $8.68 per share) in a private placement transaction pursuant to the Stock Purchase Agreement dated as of March 31, 2023 between the reporting person and the Issuer. The Series A Preferred Stock may be converted to Common Stock on a one-for-one basis at the option of the holder thereof. The reporting person has agreed not to convert his Series A Preferred Stock to the extent such conversion would require shareholder approval pursuant to Nasdaq listing rules and such shareholder approval has not been obtained.

F1 · derivative.expiration_date: On May 19, 2023, the reporting person purchased directly from the Issuer 225,000 shares of Common Stock and 351,037 shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") for a total purchase price of approximately $5,000,000 (or $8.68 per share) in a private placement transaction pursuant to the Stock Purchase Agreement dated as of March 31, 2023 between the reporting person and the Issuer. The Series A Preferred Stock may be converted to Common Stock on a one-for-one basis at the option of the holder thereof. The reporting person has agreed not to convert his Series A Preferred Stock to the extent such conversion would require shareholder approval pursuant to Nasdaq listing rules and such shareholder approval has not been obtained.

SEC source: 0001140361-23-026101 · form4.xml · nonDerivative · entry 1

Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 327,385

F1 · shares: On May 19, 2023, the reporting person purchased directly from the Issuer 225,000 shares of Common Stock and 351,037 shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") for a total purchase price of approximately $5,000,000 (or $8.68 per share) in a private placement transaction pursuant to the Stock Purchase Agreement dated as of March 31, 2023 between the reporting person and the Issuer. The Series A Preferred Stock may be converted to Common Stock on a one-for-one basis at the option of the holder thereof. The reporting person has agreed not to convert his Series A Preferred Stock to the extent such conversion would require shareholder approval pursuant to Nasdaq listing rules and such shareholder approval has not been obtained.

SEC source: 0001140361-22-026995 · form4.xml · derivative · entry 1

Hyman Steven · CIK 0001656506 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,753

Underlying: Common Stock · 57,753 shares

Expires 2032-07-25

F1 · derivative.exercise_date: The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date.

SEC source: 0001140361-22-027144 · form4.xml · derivative · entry 1

Hyman Steven · CIK 0001656506 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,753

Underlying: Common Stock · 57,753 shares

Expires 2032-07-25

F1 · derivative.exercise_date: The options were granted pursuant to the director compensation plan. 17,753 options will vest in full on the first anniversary of the grant date and 40,000 options will vest monthly pro rata over 36 months starting on the grant date.

SEC source: 0001140361-22-023331 · form4.xml · derivative · entry 1

CONRADES GEORGE H · CIK 0001106231 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2032-06-14

F1 · derivative.exercise_date: The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date.

SEC source: 0001140361-22-023335 · form4.xml · derivative · entry 1

MCGUIRE TERRANCE · CIK 0001117003 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2032-06-14

F1 · derivative.exercise_date: The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date.

SEC source: 0001140361-22-023333 · form4.xml · derivative · entry 1

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2032-06-14

F1 · derivative.exercise_date: The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date.

SEC source: 0001140361-22-023329 · form4.xml · derivative · entry 1

DESOUZA ERROL B · CIK 0001213895 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2032-06-14

F1 · derivative.exercise_date: The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date.

SEC source: 0001140361-22-023334 · form4.xml · derivative · entry 1

Mendelsohn Michael · CIK 0001591109 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2032-06-14

F1 · derivative.exercise_date: The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date.

SEC source: 0001140361-22-023332 · form4.xml · derivative · entry 1

Lovell Stephanie · CIK 0001772054 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2032-06-14

F1 · derivative.exercise_date: The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date.

SEC source: 0001140361-22-023330 · form4.xml · derivative · entry 1

Isacson Ole · CIK 0001772001 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2032-06-14

F1 · derivative.exercise_date: The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date.

SEC source: 0001140361-22-002453 · form4.xml · derivative · entry 2

Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 430,000

Underlying: Common Stock · 430,000 shares

Expires 2032-01-20

F2 · derivative.exercise_date: The stock option vests and becomes exercisable as to 2.08333% of the shares of Common Stock on each monthly anniversary of January 20, 2022.

SEC source: 0001140361-22-002458 · form4.xml · derivative · entry 1

Busch Andreas · CIK 0001775029 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 135,000

Underlying: Common Stock · 135,000 shares

Expires 2032-01-20

F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 2.08333% of the shares of Common Stock on each monthly anniversary of January 20, 2022.

SEC source: 0001140361-22-002456 · form4.xml · derivative · entry 1

Gjino Anjeza · CIK 0001839068 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 135,000

Underlying: Common Stock · 135,000 shares

Expires 2032-01-20

F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 2.08333% of the shares of Common Stock on each monthly anniversary of January 20, 2022.

SEC source: 0001140361-22-002451 · form4.xml · derivative · entry 1

Gault Cheryl · CIK 0001839046 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 135,000

Underlying: Common Stock · 135,000 shares

Expires 2032-01-20

F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 2.08333% of the shares of Common Stock on each monthly anniversary of January 20, 2022.

SEC source: 0001140361-22-002453 · form4.xml · derivative · entry 1

Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,950

Underlying: Common Stock · 52,950 shares

Expires 2032-01-03

F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 8.33333% of the shares of Common Stock on each monthly anniversary of January 3, 2022.

SEC source: 0001140361-21-041210 · form4.xml · derivative · entry 1

Busch Andreas · CIK 0001775029 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2031-12-09

F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 2.08333% of the shares of Common Stock on each monthly anniversary of December 9, 2021.

SEC source: 0001140361-21-041209 · form4.xml · derivative · entry 1

Gjino Anjeza · CIK 0001839068 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2031-12-09

F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 2.08333% of the shares of Common Stock on each monthly anniversary of December 9, 2021.

SEC source: 0001140361-21-041208 · form4.xml · derivative · entry 1

Gault Cheryl · CIK 0001839046 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2031-12-09

F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 2.08333% of the shares of Common Stock on each monthly anniversary of December 9, 2021.

SEC source: 0001140361-21-022549 · form4.xml · derivative · entry 1

CONRADES GEORGE H · CIK 0001106231 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2031-06-24

F1 · derivative.exercise_date: The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date.

SEC source: 0001140361-21-022544 · form4.xml · derivative · entry 1

MCGUIRE TERRANCE · CIK 0001117003 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2031-06-24

F1 · derivative.exercise_date: The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date.

SEC source: 0001140361-21-022578 · form4.xml · derivative · entry 1

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2031-06-24

F1 · derivative.exercise_date: The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date.

SEC source: 0001140361-21-022547 · form4.xml · derivative · entry 1

DESOUZA ERROL B · CIK 0001213895 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2031-06-24

F1 · derivative.exercise_date: The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date.

SEC source: 0001140361-21-022553 · form4.xml · derivative · entry 1

Mendelsohn Michael · CIK 0001591109 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2031-06-24

F1 · derivative.exercise_date: The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date.

SEC source: 0001140361-21-022583 · form4.xml · derivative · entry 1

Lovell Stephanie · CIK 0001772054 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2031-06-24

F1 · derivative.exercise_date: The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date.